Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP31670 + momelotinib
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EP31670 + momelotinib is an investigational combination therapy being evaluated for the treatment of myelofibrosis. Momelotinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) and activin A receptor type 1 (ACVR1/ALK2), which is already approved for the treatment of myelofibrosis patients with anemia. EP31670 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) proteins, which are epigenetic readers that regulate the expression of genes involved in inflammation and cell proliferation. The combination aims to provide synergistic effects by simultaneously targeting the JAK/STAT signaling pathway and the epigenetic regulation of pro-inflammatory and pro-fibrotic genes, potentially addressing the underlying disease drivers and improving clinical outcomes such as spleen volume reduction and symptom control in patients with myelofibrosis.
- Other names
- EP31670 + momelotinibmomelotinib + EP31670
02
Targets
ACVR1 (Activin receptor type I)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on EP31670 + momelotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP31670 + momelotinib.